← Back to Search

Protease Inhibitor

VX-993 for Healthy Adults

Phase 1
Recruiting
Research Sponsored by Vertex Pharmaceuticals Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
A total body weight of more than (>) 50 kg
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

"This trial aims to assess how safe and well-tolerated different doses of VX-993 are when given intravenously to healthy volunteers, as well as how the drug moves through the body."

Who is the study for?
This trial is for healthy adults who have a BMI between 18.0 and 32.0, weigh more than 50 kg, and are non-smokers or have quit smoking for at least three months.
What is being tested?
The study is testing the safety and how the body processes different doses of VX-993, a new drug given through an IV, compared to a placebo in people without any health issues.
What are the potential side effects?
Since this is a Phase 1 trial primarily focused on safety and dosage levels, specific side effects of VX-993 are not yet known but will be closely monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I weigh more than 50 kg.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Part B: Multiple Ascending Dose (MAD)Experimental Treatment1 Intervention
Participants will be randomized to receive multiple doses of different dose levels of VX-993. The dose levels will be determined based on the data from Part A.
Group II: Part A: Single Ascending Dose (SAD)Experimental Treatment1 Intervention
Participants will be randomized to receive a single dose of different dose levels of VX-993.
Group III: Placebo Part APlacebo Group1 Intervention
Participants will be randomized to receive placebo matched to VX-993.
Group IV: Placebo Part BPlacebo Group1 Intervention
Participants will be randomized to receive multiple doses of placebo matched to VX-993.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VX-993
2024
Completed Phase 1
~160

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Vertex Pharmaceuticals IncorporatedLead Sponsor
251 Previous Clinical Trials
32,757 Total Patients Enrolled
19 Trials studying Pain
1,221 Patients Enrolled for Pain
~66 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top